CoChat

Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B

Open access

The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Self-complementary adeno-associated virus (scAAV) vectors have become a desirable vector for therapeutic gene transfer due to their ability to produce greater levels of transgene than single-stranded AAV (ssAAV). However, recent reports have suggested that scAAV vectors are more immunogenic than ssAAV. In this study, we investigated the effects of a self-complementary genome during gene therapy with a therapeutic protein, human factor IX (hF.IX). METHODS: Hemophilia B mice were injected intramuscularly with ss or scAAV1 vectors expressing hF.IX. The outcome of gene transfer was assessed, including transgene expression as well as antibody and CD8⁺ T cell responses to hF.IX. RESULTS: Self-complementary AAV1 vectors induced similar antibody responses (which eliminated systemic hF.IX expression) but stronger CD8⁺ T cell responses to hF.IX relative to ssAAV1 in mice with F9 gene deletion. As a result, hF.IX-expressing muscle fibers were effectively eliminated in scAAV-treated mice. In contrast, mice with F9 nonsense mutation (late stop codon) lacked antibody or T cell responses, thus showing long-term expression regardless of the vector genome. CONCLUSIONS: The nature of the AAV genome can impact the CD8⁺ T cell response to the therapeutic transgene product. In mice with endogenous hF.IX expression, however, this enhanced immunogenicity did not break tolerance to hF.IX, suggesting that the underlying mutation is a more important risk factor for transgene-specific immunity than the molecular form of the AAV genome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1479-5876-12-25

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Outcome of gene transfer with ss or scAAV1 in HB mice. HB mice were injected i.m. with 1011 vg of ss or scAAV1-CMV-hF.IX (n = 4/group). Plasma was collected 1, 2, and 4 weeks post-injection. (A) Circulating hF.IX levels were measured by ELISA. (B) Anti-hF.IX IgG1 levels in plasma were measured by ELISA. (C) Bethesda titer. One BU represents the inhibition of 50% of clotting activity. (D-E) Splenocytes were harvested and restimulated with media alone, the CD8 epitope of hF.IX, or SEB, and IFN-γ spot-forming units (per 106 cells) were measured by ELISPOT. Measurements were performed on individual animals two weeks (D) or four weeks (E) post-injection. Data points are averages ± SEM. Results are representative of at least two independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001, ns = not significant.
Figure 1 Outcome of gene transfer with ss or scAAV1 in HB mice. HB mice were injected i.m. with 1011 vg of ss or scAAV1-CMV-hF.IX (n = 4/group). Plasma was collected 1, 2, and 4 weeks post-injection. (A) Circulating hF.IX levels were measured by ELISA. (B) Anti-hF.IX IgG1 levels in plasma were measured by ELISA. (C) Bethesda titer. One BU represents the inhibition of 50% of clotting activity. (D-E) Splenocytes were harvested and restimulated with media alone, the CD8 epitope of hF.IX, or SEB, and IFN-γ spot-forming units (per 106 cells) were measured by ELISPOT. Measurements were performed on individual animals two weeks (D) or four weeks (E) post-injection. Data points are averages ± SEM. Results are representative of at least two independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001, ns = not significant.CC BY · PubMed Central
Figure 2 Local hF.IX expression and CD8 infiltration in HB mice. Skeletal muscle from HB mice injected i.m. with 1011 vg ss or scAAV1 (n = 4/group) was harvested, cryosectioned, and stained for hF.IX (red) and CD8 (green). Nuclei were visualized with DAPI (blue). Two weeks post-injection, tissue was analyzed from mice injected with ssAAV1 (A-B) or scAAV1 (E-F). After four weeks, skeletal muscle was stained from mice injected with ssAAV1 (C-D) or scAAV1 (G-H). Representative images from two mice are shown for each condition. The scale bar represents 100 μm. Results are representative of at least two independent experiments.
Figure 2 Local hF.IX expression and CD8 infiltration in HB mice. Skeletal muscle from HB mice injected i.m. with 1011 vg ss or scAAV1 (n = 4/group) was harvested, cryosectioned, and stained for hF.IX (red) and CD8 (green). Nuclei were visualized with DAPI (blue). Two weeks post-injection, tissue was analyzed from mice injected with ssAAV1 (A-B) or scAAV1 (E-F). After four weeks, skeletal muscle was stained from mice injected with ssAAV1 (C-D) or scAAV1 (G-H). Representative images from two mice are shown for each condition. The scale bar represents 100 μm. Results are representative of at least two independent experiments.CC BY · PubMed Central
Figure 3 Outcome of gene transfer with ss or scAAV1 in LS mice. LS mice were injected i.m. with 1011 vg of ss or scAAV1-CMV-hF.IX (n = 4/group). Plasma was collected 1, 2, and 4 weeks post-injection. (A) Circulating hF.IX levels were measured by ELISA. (B) Anti-hF.IX IgG1 levels in plasma were measured by ELISA. (C) Bethesda titer. One BU represents the inhibition of 50% of clotting activity. (D) Splenocytes were harvested four weeks post-injection and restimulated with media alone, the CD8 epitope of hF.IX, or SEB, and IFN-γ spot-forming units (per 106 cells) were measured by ELISPOT. Measurements were performed on individual animals. (E) Circulating hF.IX levels in C57BL/6 RAG-/- mice 2 weeks post-injection with ss or scAAV1-CMV-hF.IX (n = 4/group). Data points are averages ± SEM. Results are representative of at least two independent experiments. * P < 0.05, *** P < 0.001, ns = not significant.
Figure 3 Outcome of gene transfer with ss or scAAV1 in LS mice. LS mice were injected i.m. with 1011 vg of ss or scAAV1-CMV-hF.IX (n = 4/group). Plasma was collected 1, 2, and 4 weeks post-injection. (A) Circulating hF.IX levels were measured by ELISA. (B) Anti-hF.IX IgG1 levels in plasma were measured by ELISA. (C) Bethesda titer. One BU represents the inhibition of 50% of clotting activity. (D) Splenocytes were harvested four weeks post-injection and restimulated with media alone, the CD8 epitope of hF.IX, or SEB, and IFN-γ spot-forming units (per 106 cells) were measured by ELISPOT. Measurements were performed on individual animals. (E) Circulating hF.IX levels in C57BL/6 RAG-/- mice 2 weeks post-injection with ss or scAAV1-CMV-hF.IX (n = 4/group). Data points are averages ± SEM. Results are representative of at least two independent experiments. * P < 0.05, *** P < 0.001, ns = not significant.CC BY · PubMed Central
Figure 4 Local hF.IX expression and CD8 infiltration in LS mice. Skeletal muscle from LS mice injected i.m. with 1011 vg ss or scAAV1 (n = 4/group) was harvested, cryosectioned, and stained for hF.IX (red) and CD8 (green). Nuclei were visualized with DAPI (blue). Four weeks post-injection, tissue was harvested from mice injected with ssAAV1 (A-B) or scAAV1 (C-D). Representative images from two mice are shown for each condition. The scale bar represents 100 μm. Results are representative of at least two independent experiments.
Figure 4 Local hF.IX expression and CD8 infiltration in LS mice. Skeletal muscle from LS mice injected i.m. with 1011 vg ss or scAAV1 (n = 4/group) was harvested, cryosectioned, and stained for hF.IX (red) and CD8 (green). Nuclei were visualized with DAPI (blue). Four weeks post-injection, tissue was harvested from mice injected with ssAAV1 (A-B) or scAAV1 (C-D). Representative images from two mice are shown for each condition. The scale bar represents 100 μm. Results are representative of at least two independent experiments.CC BY · PubMed Central
Figure 5 Anti-capsid antibody response. Plasma from HB or LS mice injected i.m. with 1011 vg of ss (n = 19) or scAAV1 (n = 18) was analyzed for the formation of anti-AAV1 IgG2a by ELISA 4 weeks post-injection. Data points represent individual mice, and the error bars show mean ± SEM. ns = not significant.
Figure 5 Anti-capsid antibody response. Plasma from HB or LS mice injected i.m. with 1011 vg of ss (n = 19) or scAAV1 (n = 18) was analyzed for the formation of anti-AAV1 IgG2a by ELISA 4 weeks post-injection. Data points represent individual mice, and the error bars show mean ± SEM. ns = not significant.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 61 references

Cited by

See all 45

Metadata

Authors
Rogers, G. L., Martino, A. T., Zolotukhin, I., Ertl, H. C., & Herzog, R. W.
Affiliations
  • University of Florida Health (US)
  • The Wistar Institute (US)
Corresponding author
Herzog, Roland W
Venue
Journal of Translational Medicine
Published
2014-01-25
Volume
12
Issue
1
Pages
25-25
ISSN
1479-5876 (ISSN-L)
OpenAlex
W2131782840
Cited by
45
References
62
Citations by year
2026: 3 · 2025: 1 · 2024: 3 · 2023: 5 · 2021: 8 · 2020: 2 · 2019: 4 · 2018: 2 · 2017: 6 · 2016: 4 · 2015: 4 · 2014: 3
FWCI
3.71
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal of Translational Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • University of Florida Digital Collections (University of Florida) (submittedVersion)
Funders
  • University of Florida
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute (P01HL078810)
  • National Cancer Institute (P30CA010815)
  • National Institute of Allergy and Infectious Diseases (R01AI051390, R01 AI51390)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (P01 HD078810)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
self-complementary AAV, adeno-associated virus vectors, hemophilia B, factor IX, CD8+ T cell responses, antibody response, vector immunogenicity, gene therapy
MeSH terms
Dependovirus, Animals, Antibodies, Viral, Capsid, Hemophilia B, Factor IX, Genetic Vectors, Humans, Immunity, Genetic Therapy, Genome, Gene Transfer Techniques, Codon, Nonsense, CD8-Positive T-Lymphocytes, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B. https://app.cochat.ai/papers/10.1186/1479-5876-12-25
The paper
Rogers, G. L., Martino, A. T., Zolotukhin, I., Ertl, H. C., & Herzog, R. W. (2014). Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B. Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-12-25

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.